Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth
GKOS•Glaukos reported third-quarter revenue of $211 million, up 58% year over year and above the $168.05 million consensus estimate. It raised 2026 sales guidance to $775 million-$785 million and introduced preliminary 2027 guidance of $1 billion.
1. Revenue and earnings
Glaukos reported third-quarter revenue of $211 million, up 58% year over year and above the $168.05 million analyst consensus. Adjusted net income was $28.50 million, compared with the $5.37 million adjusted net loss analysts expected; net income was $2 million.
2. Sales outlook and drivers
The company raised its 2026 net sales guidance to $775 million-$785 million from $680 million-$700 million and introduced preliminary 2027 net sales guidance of $1 billion. Glaukos cited iDose TR and Epioxa as key growth drivers. Corneal Health sales more than doubled year over year, while U.S. Glaucoma sales grew 47%.
